Double Chin Drug Kybella Following Botox Lead Says Kythera CEO

Kythera has high expectations for the targeted launch of its FDA-approved double chin injection Kybella in the second half of 2015, said the company's CEO Keith Leonard. Leonard added that his management team is comprised of a number of veterans from Botox-maker Allergan, as well as Amgen, which should reassure doctors, patients and Wall Street analysts with regard to Kybella's rollout. He said patients seek this non-surgical treatment that contours the area under the chin in order to boost self-esteem. Finally, Leonard said Kythera plans to promote Kybella independently in the U.S., but may seek a partner in foreign markets due to the uniqueness of each territory.